The evidence of the effectiveness of statins in the treatmentof stable coronary heart disease (CHD) continues to grow. Large-scale,randomized, secondary-prevention trials involving patients withCHD have shown that statins reduce the clinical consequencesof atherosclerosis, including death from cardiovascular causes,nonfatal myocardial infarction, nonfatal stroke, hospitalizationfor unstable angina pectoris and heart failure, as well as theneed for coronary revascularization. Current guidelines recommenda low-density lipoprotein (LDL) cholesterol level of less than100 mg per deciliter (2.6 mmol per liter) as the goal for patientswith stable CHD and a goal of 70 mg per deciliter (1.8 . . . [Full Text of this Article]
Source Information
From the University of Michigan School of Medicine, Ann Arbor.
This editorial was published at www.nejm.org on March 8, 2005.
This article has been cited by other articles:
Levitt, E. S., Clark, M. J., Jenkins, P. M., Martens, J. R., Traynor, J. R.
(2009). Differential Effect of Membrane Cholesterol Removal on {micro}- and {delta}-Opioid Receptors: A PARALLEL COMPARISON OF ACUTE AND CHRONIC SIGNALING TO ADENYLYL CYCLASE. J. Biol. Chem.
284: 22108-22122
[Abstract][Full Text]
Lavie, C. J., Milani, R. V., O'Keefe, J. H.
(2007). Statin Wars-Emphasis on Potency vs Event Reduction and Safety?. Mayo Clin Proc.
82: 539-542
[Full Text]
de Lusignan, S., Belsey, J., Hague, N., Dhoul, N., van Vlymen, J.
(2006). Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study. J Public Health (Oxf)
28: 361-369
[Abstract][Full Text]
Cohen, J. S., East, J. E., Elkind, M. S.V., Khan, N. A., Mascitelli, L., Pezzetta, F., Welch, K.M.A., the SPARCL Investigators, , Kent, D.
(2006). Statin Therapy after Stroke or Transient Ischemic Attack. NEJM
355: 2368-2371
[Full Text]
Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., Braunwald, E.
(2006). Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy. J Am Coll Cardiol
48: 438-445
[Abstract][Full Text]
Pedersen, T. R., Faergeman, O., Kastelein, J. J. P., Olsson, A. G., Tikkanen, M. J., Holme, I., Larsen, M. L., Bendiksen, F. S., Lindahl, C., Szarek, M., Tsai, J., for the Incremental Decrease in End Points Through,
(2005). High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial. JAMA
294: 2437-2445
[Abstract][Full Text]
Cannon, C. P.
(2005). The IDEAL Cholesterol: Lower Is Better. JAMA
294: 2492-2494
[Full Text]
Wartofsky, L.
(2005). Update in Endocrinology. ANN INTERN MED
143: 673-682
[Full Text]
Williams, K. J., Tabas, I.
(2005). Lipoprotein Retention--and Clues for Atheroma Regression. Arterioscler. Thromb. Vasc. Bio.
25: 1536-1540
[Abstract][Full Text]
Ong, H.T.
(2005). The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM
98: 599-614
[Abstract][Full Text]
Auer, J., Lamm, G., Eber, B., Cannon, C. P., Murphy, S. A., Braunwald, E., Ravnskov, U., Rosch, P. J., Sutter, M. C., Modest, G. A., Southern, W., LaRosa, J. C., Grundy, S. M., Waters, D. D.
(2005). Intensive lipid lowering with atorvastatin in coronary disease.. NEJM
353: 93-96
[Full Text]
Lerman, B. B., Devereux, R. B., Okin, P. M.
(2005). An Introduction. J Am Coll Cardiol
45: B2-B3
[Full Text]
Beckley, E. T.
(2005). Cardiologists Share CVD Risk-Reduction Research. DOC News
2: 1-7
[Full Text]
Previous
